A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo­Controlled Trial to Evaluate the Efficacy and the Safety of Efgartigimod (ARGX-113) PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia

  • Kaplan, Zane (Primary Chief Investigator (PCI))

Project: Research

Project Details

StatusActive
Effective start/end date25/03/21 → 24/03/26

Keywords

  • phase 3 study
  • treatment efficacy
  • treatment safety
  • Immune Thrombocytopenia